• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Emepepimut-S for non-small cell lung cancer.
【24h】

Emepepimut-S for non-small cell lung cancer.

机译：Emepepimut-S用于非小细胞肺癌。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

INTRODUCTION: Immunotherapy as a possible therapeutic option for cancer has been of great importance due to the innovative development of vaccines. Various molecules have been tested and emepepimut-S (Biomira Liposomal Peptide 25 (BLP 25)) has emerged as an option, particularly in lung cancer. AREAS COVERED: A PubMed literature and ClinicalTrials.gov search was conducted using the terms: emepepimut, BLP25, NSCLC, cancer immunotherapy, cancer vaccine and MUC1. This review covers how emepepimut-S acts against the mucin 1 (MUC1) tumor-associated antigen producing a cellular immune response against the cells that express MUC1 and the most important clinical data available that led to the ongoing Phase III trial. EXPERT OPINION: The results obtained in the Phase I/II trials are promising, showing a favorable toxicity with a benefit in survival in NSCLC patients. As future trials develop, demonstration of the long-term survival benefit, understanding of the various mechanisms of immune response initiated by the drug and the selection of patients that will highly benefit from the immunotherapy will be elucidated. The safety and extension in survival makes emepepimut-S a very interesting drug and could, therefore, offer a possibility of treatment and maintenance, particularly for good performance status patients with locally advanced NSCLC.
机译：引言：由于疫苗的创新发展，免疫疗法作为癌症的一种可能的治疗选择已变得非常重要。已经测试了多种分子，并且出现了艾美美普莫特-S（Biomira脂质体肽25（BLP 25））作为一种选择，特别是在肺癌中。覆盖区域：使用以下术语进行了PubMed文献和ClinicalTrials.gov搜索：emepepimut，BLP25，NSCLC，癌症免疫疗法，癌症疫苗和MUC1。这篇综述涵盖了emepepimutmut-S如何对抗粘蛋白1（MUC1）肿瘤相关抗原产生针对表达MUC1的细胞的细胞免疫应答，以及导致正在进行的III期试验的最重要的临床数据。专家意见：I / II期试验获得的结果令人鼓舞，显示出良好的毒性，对NSCLC患者的生存有利。随着未来的试验发展，将阐明长期生存获益的证明，对药物引发的各种免疫反应机制的了解以及将从免疫疗法中高度受益的患者的选择。安全性和生存期的延长使emepepimut-S成为一种非常有趣的药物，因此可以提供治疗和维持的可能性，尤其是对于局部晚期NSCLC表现良好的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号